GeoVax faces Nasdaq delisting hearing Oct 13 over bid price; stock continues trading

GeoVax Labs, Inc.

Received Nasdaq delisting determination Aug 27, 2026 for failing minimum bid price (Rule 5550(a)(2)).
Hearing before Nasdaq Hearings Panel scheduled for Oct 13, 2026; suspension/delisting stayed pending hearing.
Common stock continues trading on Nasdaq Capital Market under GOVX through hearing and any extension.
Company to present plan to regain compliance; reaffirms GEO-MVA pivotal Phase 3 and Gedeptin oncology progress.
CEO David Dodd cites vaccine supply resilience and biodefense preparedness as strategic focus.

Featured in Daily 8-K Digest

Selected #6 for 2026-09-10. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.